FP4Индивидуална стипендия

Identification of viral nuclear-homing proteins and their use for improved delivery of therapeutic genes using semi-synthetic vectors

4РП — Обучение и мобилност на изследователи

Период
Финансиране от ЕС
Участници
1
Схема

Линиите свързват координатора с партньорите.

Накратко на български

Вирусни протеини се търсят за по-ефективно транспортиране на лечебни гени чрез наночастици директно в ядрото на клетката. Това помага за подобряване на методите за доставка на генетичен материал при генната терапия.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

Research objectives and content. This project will develop efficient systems for targeted delivery of genes to cells,. It is an interdisciplinary project, combining my own expertise in cloning with expertise of my supervisors in viral infectivity and development of synthetic systems for gene delivery. The primary objective of the research project is to identify viral proteins capable of mediating nuclear delivery of DNA-containing nanoparticles for gene therapy. Individual objectives include: ? Identifying methods for efficient attachment of viral proteins onto DNA nanoparticles. ? Determine intracellular distributions of nanoparticles in cells by confocal microscopy ? Identification of viral proteins capable of promoting nuclear accumulation ? Evaluation of usefulness of these proteins in mediating transfection of cells in vitro. Training content (objective, benefit and expected impact) The Institute for Cancer Studies has a very good international reputation for gene therapy, and also in the study of viruses in oncology. There are few places in the world which combine these expertises. I expect to learn techniques of tissue culture, handling of DNA, reporter gene assays, microinjection and confocal analysis of intracellular distribution,. This should enable me afterwards to find good employment in this field, probably in Germany. Links with industry: The MRC Gene Therapy Programme has strong links with Glaxo/Wellcome, and Dr Seymour has increasingly strong links with Zeneca. (200 words not counting titles)

Оригинален текст от CORDIS (на английски).

Участници

  • Aristotle University of Thessaloniki · ThessalonikiКоординаторГърция

Връзки

Данни: CORDIS, © Европейски съюз